A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models

被引：2
|
作者：
Mikami, Hirofumi
Feng, Shu
Naoi, Sotaro
Azuma, Yumiko
Kayukawa, Yoko
Tsunenari, Toshiaki
Asanuma, Kentaro
Iwabuchi, Ryutaro
Nagano, Hiroaki
Shinozuka, Junko
Yamazaki, Masaki
Kuroi, Haruka
Gan, Siok Wan
Chichili, Priyanka
Shimizu, Shun
Matsuda, Yutaka
Ishii, Shinya
Kamikawaji, Shogo
Kinoshita, Yasuko
Shimizu, Yuichiro
Sakamoto, Akihisa
Muraoka, Masaru
Takahashi, Noriyuki
Kawa, Tatsuya
Shiraiwa, Hirotake
Kashima, Kenji
Mimoto, Futa
Kamata-Sakurai, Mika
Kitazawa, Takehisa
Igawa, Tomoyuki
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1872
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1872
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Potent antitumor activity of duvortuxizumab, a CD19 x CD3 DART® molecule, in lymphoma models
    Izhak, Liat
    Cullen, Dana E.
    Elgawly, Maha
    Luistro, Leopoldo
    Johnson, Syd
    Bald, Jaime
    Sasser, A. Kate
    Balasubramanian, Sriram
    CANCER RESEARCH, 2017, 77
  • [42] IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
    Jaspers, Janneke E.
    Khan, Jonathan F.
    Godfrey, William D.
    Lopez, Andrea, V
    Ciampricotti, Metamia
    Rudin, Charles M.
    Brentjens, Renier J.
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (09):
  • [43] CD3ε tunes CAR T cell anticancer activity
    Alexandra Flemming
    Nature Reviews Immunology, 2020, 20 : 520 - 521
  • [44] CD3ε tunes CAR T cell anticancer activity
    Flemming, Alexandra
    NATURE REVIEWS IMMUNOLOGY, 2020, 20 (09) : 520 - 521
  • [45] The combination therapy with EpCAM/CD3 BsAb and MUC-1/CD3 BsAb elicited antitumor immunity by T-cell adoptive immunotherapy in lung cancer
    Wang, Ce
    Chen, Shang
    Wu, Yingjuan
    Wu, Di
    Wang, Jingbo
    Li, Furong
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (15): : 3380 - 3388
  • [46] AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
    Cooke, K.
    Estrada, J.
    Zhan, J.
    Werner, J.
    Bailis, J.
    Hughes, P.
    Shetty, A.
    Canon, J.
    Smit, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S343 - S344
  • [47] Polymorphisms of the T cell receptor CD3δ and CD3ε chains affect anti-CD3 antibody binding and T cell activation
    Boding, Lasse
    Nielsen, Martin Weiss
    Bonefeld, Charlotte Menne
    von Essen, Marina Rode
    Nielsen, Bodil Lisbeth
    Lauritsen, Jens Peter H.
    Hansen, Ann Kathrine
    Nielsen, Molten Milek
    Kongsbak, Martin
    Rubin, Maria
    Vennegaard, Marie Torp
    Odum, Niels
    Geisler, Carsten
    MOLECULAR IMMUNOLOGY, 2010, 47 (15) : 2450 - 2457
  • [48] Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer
    Zhang, Huan
    Yang, Yunkai
    Li, Xuchang
    Yuan, Xun
    Chu, Qian
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 159
  • [49] Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer
    Ataee, Mohammad Hossein
    Mirhosseini, Seyed Ali
    Mirnejad, Reza
    Hosseini, Hamideh Mahmoodzadeh
    Amani, Jafar
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2025, 12
  • [50] CD28 expression on multiple myeloma cells enhances the cytotoxic activity of CD38/CD28xCD3 trispecific T cell engager
    El-Murr, Nizar
    Henry, Christophe
    Francesconi, Elisa
    Attenot, Florence
    Virone-Oddos, Angela
    Vidard, Laurent
    Wu, Lan
    Yang, Zhi-Yong
    Chiron, Marielle
    CANCER RESEARCH, 2020, 80 (16)
12345